Previous close | 30.13 |
Open | 29.99 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 29.32 - 29.99 |
52-week range | 11.14 - 30.57 |
Volume | |
Avg. volume | 256 |
Market cap | 1.527B |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.26 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 22.54 |
Company announcement – No. 58 / 2022 Total number of shares and voting rights in Zealand Pharma at December 30, 2022 Copenhagen, Denmark and Boston, MA, U.S. December 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Compa
Company announcement – No. 57 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark and Boston, MA, U.S. December 8, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 64,919 divided into 64,919 new shares with a nominal value of
Company announcement – No. 56/ 2022 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark and Boston, MA, U.S. December 2, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's share